Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Accumulated Expenses (2018 - 2025)

Arcturus Therapeutics Holdings' Accumulated Expenses history spans 8 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 47.78% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $6.9 million, down 47.78%, while the annual FY2025 figure was $6.9 million, 47.78% down from the prior year.
  • Accumulated Expenses reached $6.9 million in Q4 2025 per ARCT's latest filing, up from $5.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $52.4 million in Q3 2021 to a low of $5.0 million in Q3 2025.
  • Average Accumulated Expenses over 5 years is $19.6 million, with a median of $11.8 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 1722.63% in 2021, then tumbled 85.1% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $23.5 million in 2021, then rose by 28.52% to $30.2 million in 2022, then crashed by 80.42% to $5.9 million in 2023, then skyrocketed by 124.82% to $13.3 million in 2024, then crashed by 47.78% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Accumulated Expenses are $6.9 million (Q4 2025), $5.0 million (Q3 2025), and $5.7 million (Q2 2025).